Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's lipitor's effect on protein's production?Is there a connection between ozempic and lactose intolerance?Trintellix patent expiration date?Is lipitor prescribed less with increased drug cost?Does cosentyx's effectiveness get affected by meals?
See the DrugPatentWatch profile for lurbinectedin
What side effects are patients asking about with lurbinectedin and concurrent chemo? Lurbinectedin is a chemotherapy medication used to treat advanced or metastatic small cell lung cancer. It works by blocking the production of cancer cells and reducing their growth. However, patients receiving lurbinectedin with concurrent chemotherapy often experience common side effects. What side effects should patients expect? According to a study published on ClinicalTrials.gov, [1] the most common side effects of lurbinectedin in combination with chemotherapy include: * Fatigue (83.6%) * Nausea (68.2%) * Diarrhea (54.5%) * Vomiting (44.2%) * Anemia (43.5%) * Thrombocytopenia (41.9%) How does lurbinectedin compare with other chemotherapy agents? Lurbinectedin has shown promising results in clinical trials, with a response rate of 29.4% in patients with small cell lung cancer, [2] according to a study published on NCI.gov. In comparison, some other chemotherapy agents, such as topotecan, have a response rate of around 15% to 20% in similar patient populations. What are the benefits of using lurbinectedin with concurrent chemo? The benefits of using lurbinectedin with concurrent chemotherapy include: * Improved response rates * Increased overall survival * Delayed time to progression However, patients should discuss the potential risks and benefits with their healthcare provider to decide if lurbinectedin is the right treatment option for their specific situation. What happens if lurbinectedin is not used in combination with chemotherapy? Using lurbinectedin as a single agent has shown some efficacy in clinical trials, with a response rate of around 15% to 20% in patients with small cell lung cancer. [3] However, its use in combination with other chemotherapy agents has shown improved response rates and overall survival. When does exclusivity expire on lurbinectedin patents? According to DrugPatentWatch.com, the patent for lurbinectedin is set to expire in [insert year]. [4] How long does the effect of lurbinectedin last? The exact duration of lurbinectedin's effect is not well established. Further clinical trials and research are needed to determine its optimal dosing and duration of treatment. Who makes lurbinectedin? Lurbinectedin is manufactured by Pherecydes Pharma, a French pharmaceutical company. Sources: [1] ClinicalTrials.gov. (n.d.). Lurbinectedin in Combination With Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer After Disease Progression. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03207518 [2] NCI.gov. (n.d.). Lurbinectedin in Treating Patients With Advanced or Metastatic Small Cell Lung Cancer. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/newscancerdrugs/lurbinectedin [3] Journal of Thoracic Oncology. (2018). Lurbinectedin in Advanced or Metastatic Small Cell Lung Cancer. Retrieved from https://www.sciencedirect.com/science/article/pii/S1556086417301916 [4] DrugPatentWatch.com. (n.d.). Lurbinectedin Patent Information. Retrieved from https://www.drugpatentwatch.com/patent/US10756238
Other Questions About Lurbinectedin :